Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

Caring for someone with ATTR amyloidosis can be physically and emotionally demanding. To reduce the chances of burnout, caregivers should also prioritize their own well-being. Factors such as ...

Supporting a loved one with transthyretin amyloidosis (ATTR-CM) to remain active involves encouraging familiar routines, managing energy levels, and fostering social connections to enhance their ...

Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival. Long-term ATTR-CM trial data show durable benefits ...

One couple shares their caregiving experience as hATTR-CM impacts their lives. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive condition where the transthyretin (TTR) protein ...

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Prothena has now earned $150 million to date of the $1.2 billion total ...

Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ...

There is a hereditary form of transthyretin amyloid cardiomyopathy (ATTR-CM) caused when a mutated gene is passed from parent to child. Having the mutation does not mean you will develop the disease, ...